The new IMBA building
IMBA - Institute of Molecular Biotechnology GmbH

Dr. Bohr-Gasse 3-5
1030 Vienna
Austria

Phone: +43(1)79730
Fax: +43(1)79730/459
www.imba.oeaw.ac.at

For a copy of this report please contact the IMP-IMBA Public Relations Department
e-mail: info@imba.oeaw.ac.at

IMBA and IMP operate in partnership as a joint initiative of the Austrian Academy of Sciences and Boehringer Ingelheim.
IMBA is a member of the Campus Vienna Biocenter.
Contents

Introduction 4
Your career at IMBA 6

Research Groups
Barry DICKSON 8
Jürgen KNOBLICH 10
Javier MARTINEZ 12
Josef PENNINGER 14
Vic SMALL 16
Drosophila RNAi group 18

Scientific Services
Biooptics Department 19
Service Department 20
Protein Chemistry Facility 21
Animal House and Mouse Service Department 22

Awards and honours 23
Administration and other Services 24
Publications 26
Seminar speakers 30
The Scientific Advisory Board 32
The Supervisory Board 33
Social life 34
Impressum 36
Introduction

Josef Penninger
December 2004

This is the first Annual Report of IMBA and it is time to look back at our beginning. It has been an interesting ride. Much has been accomplished. Much needs to be done.

IMBA was founded as a subsidiary of the Austrian Academy of Sciences with support from the Federal Government and the City of Vienna. IMBA has good and close ties with our partners, the Research Institute of Molecular Pathology (IMP) and Boehringer Ingelheim. IMP and IMBA share infrastructure to strengthen the already world-class services at the IMP and to allow IMBA investigators to have rapid access to such services. The contract that guarantees equal access of researchers from IMBA and IMP to the services has been signed. We are grateful to everyone at the IMP, in particular to the members of the service departments, for their generous and cooperative spirit in this endeavor. We view this service agreement as a significant milestone in the establishment of IMBA, and the cornerstone of our future cooperation with the IMP.

When I arrived 18 months ago from Canada our partner, the IMP, gave us space to set up shop. Thus, IMBA was physically born. We were very fortunate to welcome Barry Dickson and Jürgen Knoblich, two former IMP members as the first Senior Scientists. Barry Dickson’s group works on neurobiology and Jürgen Knoblich’s group on stem cells and cell polarity genes. Javier Martinez joined us from the Rockefeller University as a junior scientist. His group works on the mechanism of RNAi. We are also privileged that Victor Small decided to join IMBA and bring to us his great expertise in cell migration and imaging. Last but not least, I won over Michael Krebs as co-director of IMBA who became responsible for budgeting, financing, and business development allowing me to focus on research. Many people including members of our search committee and Scientific Advisory Board have been involved in these recruitments. I am indebted to you all.

On a personal note I have to say that we indeed have splendid partners at all levels of the IMP and at the Academy of Sciences. My particular thanks go to Kim Nasmyth, IMP; Andreas Barner, Boehringer Ingelheim, Werner Welzig, the past and present Presidium of the Austrian Academy of Sciences, the Board of Directors, and Scientific Advisory Board for their help and support in sometimes difficult times. Without them, IMBA would not exist. All IMBA members have best intentions and will try everything to make this cooperation work and to contribute to the success of our sister institution.

To paraphrase John F. Kennedy: We are building IMBA, not because it is easy, but because it is hard. The challenge is one that we are willing to accept, one we are unwilling to postpone, and one we intend to win. The future will be indeed exciting. We had a great beginning.
2004 has been the first year of full operations for IMBA and a year of great achievements and tremendous growth. Since 2003, IMBA has built up a research workforce of over 80 scientists working in six independent research groups and almost 20 people in scientific and administrative support functions.

This unbelievable growth has only been possible because IMBA could rely on its strong research partnership with the Research Institute of Molecular Pathology (IMP) - one of the most prominent scientific institutes for basic research in Europe. Based on an agreement to a shared service concept, IMBA has been provided access to one of the crown jewels of the IMP: their world-class scientific services. We are very pleased to be able to build our institute on that high level of experience right from the beginning. Equally, we hope to be able to contribute to this high service quality and to generate synergies that are of mutual benefit to both institutes.

One of the major challenges in 2004 has been the construction of our new research building at the “Campus Vienna Biocenter”. For the time being, the work is well in progress and will be terminated as expected by the end of 2005. The new research facility will offer a state-of-the-art infrastructure for up to 200 researchers, thus creating a very competitive environment in the molecular biology research landscape in Austria. In this context, we thank our public sponsors such as the City of Vienna, the Ministry of Science, Education, and Culture (BMBWK) as well as the National Foundation for their substantial financial contributions.

In 2004, IMBA operated with a research budget of around € 10 m, thereof € 7.5 m came from financial commitments of the Austrian government and the Austrian Academy of Sciences. In addition to this, IMBA scientists raised more than € 2.5 m in research grants from the Austrian Science Fund (FWF), GENAU, the Austrian National Bank, and from the 6th Framework Programme of the EU. To get the institute off the ground, IMBA will mostly rely on public funding in the near future. However, we are highly committed to exploit new sources for financing the future growth of the institute through private sponsorship activities and the commercialization of our research.

One of the reasons why I joined IMBA was its strong commitment to world-class science and its dedication to translating the basic discoveries into novel approaches to human medicine. In this context, we are very excited to initiate a unique platform for drug target discovery based on a Drosophila RNAi Screening Library that has been developed by Barry Dickson and his research group. Through partnerships with the pharmaceutical industry and academic institutions, IMBA expects to gain a very high visibility and reputation within the scientific community.

Thank you to everybody at IMBA for your exceptional commitment and your tolerance and patience with the bottlenecks and problems we have been facing in the process of implementing the IMBA infrastructure from the scratch. Also, thank you to all the IMP members for hosting us and for the continuous support in setting-up the institute and managing the past headcount growth.

The management team is committed to shape IMBA into one of the leading Centers of Excellence in Molecular Biology in Europe; your dedication and engagement is the basis for delivering on this promise.

Michael Krebs
December 2004
Your career at IMBA

The establishment of any institution depends on the expertise and commitment of its employees. At IMBA, we believe our success stems from our highly skilled scientists who are dedicated to make a difference in molecular biology research. We are a young and rapidly growing team that is committed to provide its people with the best working environment that encourages creativity, enthusiasm, fun and collaboration among the scientific groups. Our new research facility at the Campus Vienna Biocenter and world-class scientific services shared with the IMP offer a state-of-the-art infrastructure for up to 200 researchers, representing an attractive new Center of Excellence in biomolecular research in Europe.

We offer a variety of attractive positions at all levels of research training and career. Currently, IMBA consists of 6 research groups that include 26 Postdoctoral Fellows, 27 PhD Students, 22 Technical Assistants and 3 Diploma Students representing 23 different nationalities. Graduate students join IMBA through the Vienna Biocenter International PhD Program. The doctoral degree is awarded by the University of Vienna. Selection of PhD students takes place twice a year. Information about the PhD program at the Vienna Biocenter is available at: [www.univie.ac.at/vbc/PhD](http://www.univie.ac.at/vbc/PhD).

Applicants for scientific positions are evaluated by IMBA Scientific Search Committee consisting of internationally renowned scientists: Prof. Anton Berns (Netherlands Cancer Institute, Amsterdam, The Netherlands), Prof. Meinrad Busslinger (IMP, Vienna, Austria), Prof. Kim Nasmyth (IMP, Vienna, Austria), Prof. Jeff Schatz (Swiss Science and Technology Council, Basel, Switzerland), Prof. Peter Schuster (Austrian Academy of Sciences, Vienna, Austria) and Prof. Jim Woodgett (Ontario Cancer Institute, Ontario, Canada). Positions available at IMBA are advertised at: [www.imba.oeaw.ac.at/positions](http://www.imba.oeaw.ac.at/positions).
An extensive seminar program brings internationally renowned scientists to IMBA at least once a week. Information about the seminar speakers is available at: www.imba.oeaw.ac.at/news.

Our personnel department and assistants support new team members in their relocation efforts and in settling down in Vienna. Since we are aware that moving is an important factor to spouses and kids, we are also committed to help family members of our colleagues to get acquainted with Vienna.
Assembly and function of neural circuits

All animals are born with a set of instincts, or innate behaviours. Selection has favoured the evolution of genetic programmes that "hard-wire" these behaviours into the nervous system. We seek to unravel these programmes - to understand how genes direct the assembly of neural circuits, and how these circuits generate complex behaviours.

Assembly

Neural circuits are formed as individual neurons send out axons and dendrites to find, recognize, and connect with their appropriate target cells. We are using Drosophila genetics to investigate the molecular mechanisms that direct circuit assembly. We focus on two systems: the ventral nerve cord of the embryo, and the olfactory system of the adult.

In bilaterally symmetric nervous systems, such as our own and the fly’s, many axons must decide whether or not to grow across the midline. Our recent work has revealed how this decision is controlled in Drosophila (Figure 1). Crossing and non-crossing axons differ in their sensitivity to the midline repellent Slit. Both crossing and non-crossing neurons express the Slit receptor Robo. In non-crossing neurons, Robo accumulates at the tip of the axon, making it sensitive to the repulsive activity of Slit. Crossing neurons express an intracellular sorting receptor called Comm, which diverts newly synthesized Robo from the Golgi to endosomes and lysosomes for degradation. This prevents Robo from reaching the axon tip, and so the axon is insensitive to Slit and able to grow across the midline. Another guidance cue, Netrin, acts as a short-range attractive cue to help some of these axons grow across the midline. Whether or not they cross, many axons turn to grow anteriorly or posteriorly alongside the midline. These axons follow pathways at specific distances from the midline. The choice of these pathways is controlled in part by the combinatorial expression of three different Robo receptors, possibly also in response to the Slit signal from the midline.

Our sense of smell, and the fly’s, depends on the precise wiring of olfactory neurons in the nose (or the antenna) to targets in the brain. In Drosophila, each of the ~1300 olfactory receptor neurons (ORNs) in the antenna expresses one of ~60 odorant receptors. ORN axons project to the antennal lobe, a “raspberry-like” structure in the brain consisting
of ~50 “balls” called glomeruli. All ORNs that express the same odorant receptor project to the same glomerulus (Figure 2). We have determined most of the wiring diagram of the olfactory system, tracing all the connections from the ORNs in the antenna to their target glomeruli in the antennal lobe. We can now perform genetic screens to identify mutants with abnormal wiring patterns. These mutants should lead us to the genes that instruct each ORN to select its specific odorant receptor, and to connect to the corresponding glomerulus.

Figure 2: Olfactory wiring. (A) ORNs in the antenna expressing either of two different odorant receptors, Or88a (green) or Or47b (red). (B and C) ORNs that express the same odorant receptor project to the same glomerulus in the antennal lobe in the brain. The blue staining shows all the glomeruli in the antennal lobe. Red and green staining labels the axons of the same ORNs shown in A, which converge on glomeruli called DA1 and VA1v respectively.

Contact: barry.dickson@imba.oeaw.ac.at
Asymmetric cell division in Drosophila

While most cells divide into two identical daughter cells, some cell divisions are asymmetric and give rise to two different daughter cells. To achieve this, cell fate determinants localize asymmetrically during mitosis and segregate into only one of the two daughter cells. Asymmetric cell divisions are best understood in insects and in worms, yet they contribute to the development of the mammalian brain as well.

Numb belongs to a group of proteins that act as segregating determinants during the development of the Drosophila nervous system. Numb is a membrane-associated protein. It localizes asymmetrically during mitosis and segregates into one of the two daughter cells, thus establishing its fate to differentiate into a cell type different from its sister’s (Figure 1). When Numb is absent (numb mutants) or overexpressed, both daughter cells become identical. Numb is conserved in vertebrates. It seems to play a similar role in asymmetric cell divisions that take place during the mouse brain development. Our goal is to understand how Numb and other cell fate determinants localize asymmetrically in the parental cells, and how they influence the fate of one of the daughters.

Asymmetric localization of Numb, and of several other cell fate determinants, requires the conserved Par-protein complex. This complex contains the protein kinase aPKC and two PDZ domain proteins, Par-3 and Par-6. Before mitosis, the Par-complex localizes to the cell cortex at the site opposite to where Numb will accumulate. Using preparative immunoprecipitation and mass spectrometry, we identified an additional component of the Par-protein complex, the cytoskeletal protein Lgl (Figure 2A). Lgl is active at one side of the cell where it allows the recruitment of cell fate determinants to the cell cortex. At the other side of the cell, Lgl is phosphorylated by aPKC. Phosphorylation inactivates Lgl and blocks its association with the cortical actin cytoskeleton. Deletion analysis revealed that the C-terminus of Lgl associates with...
cytoplasmic myosin II. Upon phosphorylation, the N-terminus of Lgl binds to the C-terminus thus blocking myosin interaction (Figure 2B). Hence, Lgl activity is regulated by phosphorylation-induced auto-inhibition. We are using mass spectrometry to identify binding partners of the various functional domains of the Lgl to gain a better understanding of how this protein mediates the localization of cell fate determinants to the cell cortex.

How does Numb establish a particular cell fate? Genetic experiments revealed that Numb represses the activity of the transmembrane receptor Notch. In asymmetric cell divisions, Notch and its ligand Delta are present in both daughter cells. However, Notch is active only in one cell. In the other cell, Notch activity is abolished by Numb-induced endocytosis of Notch and/or of other members of the Notch pathway. Numb triggers this reaction by binding to α-Adaptin, a protein involved in receptor-mediated endocytosis. In a genetic screen for mutations that cause a phenotype similar to numb, we identified alleles of α-adaptin that specifically disrupted this interaction and displayed defects in the development of the nervous system, consistent with Numb losing its ability to suppress Notch. Like Numb, α-Adaptin is asymmetrically localized during asymmetric cell division. Numb may therefore act by polarizing the key components of the endocytic machinery. We are currently investigating the subcellular distribution of the major endocytic compartments and analyzing whether other endocytic proteins show an asymmetric distribution as well.

Figure 2: How Lgl directs asymmetric cell division. (A) In neural precursor cells, the Par-protein complex localizes asymmetrically and phosphorylates the cytoskeletal protein Lgl on one side of the cell. Phosphorylation inactivates Lgl. On the opposite side, however, non-phosphorylated Lgl is active and allows localization of cell fate determinants to the cell cortex. (B) In the active form, the C-terminus of Lgl interacts with myosin. Upon phosphorylation, however, the N-terminus binds to the C-terminus abolishing its interaction with myosin. In consequence, Lgl becomes inactive and translocates into the cytosol.

The key components of the asymmetric cell division machinery are conserved in vertebrates. Mouse Numb segregates asymmetrically during mouse brain development. The Par-complex is involved in mammalian cell polarity and, like in Drosophila, acts by phosphorylating the Lgl homolog. We have just begun to analyze mammalian homologues of genes involved in asymmetric cell division in Drosophila. We are examining their subcellular distribution, and have begun to generate knock-out mouse strains to study their respective mutant phenotypes. These experiments should provide insight into how asymmetric cell divisions contribute to mammalian development and what role they play in stem cells. Ultimately, we hope to understand to what extent asymmetric cell divisions contribute to the development of our own body.
RNA interference (RNAi) is a post-transcriptional gene silencing mechanism triggered by double-stranded RNA. The use of RNAi as a tool to silence gene expression has spread worldwide from the pioneer work done in Thomas Tuschl’s laboratory: short interfering RNA duplexes (siRNAs), consisting of 19 base-pairs and 2-nt overhangs at the 3’ end, when transfected into mammalian cells, guide degradation of homologous mRNAs with exquisite specificity. This degradation generates a knock-down phenotype, i.e. the partial or total disappearance of the targeted protein. However, research towards the elucidation of the molecular mechanism of RNAi has not followed the same pace. The main question of how do siRNAs achieve the degradation of complementary mRNAs remains unanswered. Our laboratory is taking a biochemical approach to reveal the nature of the RNAi machinery components.

RNAi biochemistry: Purification of the RISC complex

In order to elucidate the mechanism of RNAi in human cells, we developed an in vitro system that utilizes HeLa cell cytoplasmic extracts. We set out to isolate the RNA-induced silencing complex (RISC) by affinity purification using siRNA duplexes containing biotinylated photocleavable linkers on each strand. Upon incubation with HeLa cell cytoplasmic extracts, biotinylated siRNAs were captured with Streptavidin, rigorously washed, released by UV irradiation and finally recovered. The affinity-purified RISC is a 130 kDa ribonucleoprotein complex containing a single-stranded siRNA and two members of the Argonaute protein family, eIF2C1 or Argonaute 1 and eIF2C2 or Argonaute 2. Greg Hannon’s laboratory recently revealed that Argonaute 2 is the actual endonuclease of RISC.

Structural and chemical features of RISC-guided RNA cleavage.

To investigate how RISC cleaves a complementary RNA, we labeled a 21-nt long RNA substrate at the scissile phosphodiester bond. Upon RISC-guided cleavage, the radiolabeled phosphate was present as a

Figure 1: Cleavage analysis of modified substrate RNAs. (A) Sequence and position of 2’-deoxy (S21-d) and 2’-O-methyl (S21-m) modified substrates. (B) Cleavage reactions loaded into a 15% denaturing polyacrylamide gel. Substrate RNAs were labeled at the 5’ end. The arrow indicates the 5’-labeled cleavage products.
5'-phosphate at the 12-nt 3' cleavage product, indicative of a hydrolytic reaction in which cleavage products carry 3'-hydroxyl and 5'-phosphate termini. To further study the chemistry of the cleavage reaction, we synthesized short RNAs containing modifications at the 2' position of the ribose, such as deoxy or O-methyl groups. The presence of a deoxy group at the cleavage position (and nearby) did not affect the RISC activity indicating that the 2'-hydroxyl group is not essential for the cleavage (Figure 1). However, the activity was completely abolished by placing the 2'-O-methyl group at the cleavage position (G9). These results suggest that the methyl group might cause steric interference, possibly with positioning of an essential divalent metal ion required for catalysis of the cleavage reaction.

Recent reports describe off-target effects of RNAi, i.e. the “unwanted” degradation of RNAs showing extensive but not full complementarity to the siRNA duplex. We have demonstrated that RISC is able to cleave an RNA substrate as short as 15 nucleotides (Figure 2) suggesting that such extent of complementarity is sufficient for cleavage to occur. This observation should help to better design siRNAs in order to avoid off-targeting.

We have recently begun to build a siRNA-protein interaction map, using HeLa cell cytoplasmic and nuclear extracts, and radiolabeled siRNA duplexes containing 4-thio-uridines at specific positions (Figure 3). Upon UV irradiation, proteins in close proximity to the modified uridines become covalently bound to the siRNA, and thus radiolabeled. Denaturing polyacrylamide gel electrophoresis allows detection of these radiolabeled proteins, while identification is achieved by immunoprecipitation. In cytoplasmic extracts, we are able to cross-link Dicer, the RNase III endonuclease that processes dsRNAs into siRNAs, to both 3' overhangs of a siRNA duplex. Argonaute 2 becomes cross-linked to the center of the siRNA duplex in a time-dependent manner. Future experiments will focus on the identification of other siRNA binding proteins and enzymes in the RNAi pathway, like helicase/s involved in the unwinding of siRNA duplexes – a process that leads to the formation of RISC – and later in the release of the target RNA upon cleavage by RISC. In addition, it will become challenging to identify nuclear siRNA binding proteins, since siRNAs have recently been found to play a role in heterochromatin formation.

Contact: javier.martinez@imba.oeaw.ac.at
Molecular control of T cell activation

Efficient immunity requires both activation of T cells and generation of cytokines. T cell activation involves two signals: A signal via the peptide-specific TCR and a signal via a co-stimulatory receptor. Failure to activate the second signal results in T cell unresponsiveness. Thus, lack of immunity to many tumors or chronic infections can be ascribed to the fact that so affected cells cannot provide a second signal for T cell activation. By contrast, deregulated activation can trigger autoimmunity. What are the molecular mechanisms controlling T cell activation in normal physiology and in disease?

The E3 ubiquitin ligase Cbl-b, autoimmunity, and T cell tolerance

The three mammalian Cbl-family proteins, c-Cbl, Cbl-b, and Cbl-3 are RING-finger containing E3 ubiquitin ligases that control degradation, localization, receptor recycling, and protein-protein interaction of multiple signalling molecules. Genetic inactivation of c-Cbl in mice causes altered thymocyte selection whereas inactivation of Cbl-3 shows no apparent phenotype. Cbl-b mutation leads to spontaneous autoimmunity and exacerbates autoimmunity in arthritis and diabetes models. Our results provided the first molecular link between protein ubiquitination and autoimmunity.

How does Cbl-b control autoimmunity and T cell activation? Our data showed that loss of Cbl-b causes TCR-mediated T cell activation in the absence of CD28 co-stimulation and “forces” T cells to use a second signal via CD28 to form immune synapses (Figure 1). Antigen specific immune-tolerance limits the expansion of self-reactive T cells involved in autoimmune diseases. A dominant “tolerogenic” factor that represses activation of anergic T cells remains unknown. Does Cbl-b also control T cell tolerance? We have shown that Cbl-b is selectively up-regulated in T cells exposed to tolerizing antigens. Loss of Cbl-b in mice prevents induction of T cell tolerance both in vitro and in vivo. Importantly, re-challenging of Cbl-b mutant mice with tolerizing antigens causes massive lethality. It was found that loss of Cbl-b rescues the reduced calcium mobilization by anergic T cells, which is attributed to Cbl-b-mediated regulation of PLCγ-1 phosphorylation. However, yet unexplored mechanisms of Cbl-b action must exist as our results point to a critical role that Cbl-b plays in the regulation of peripheral tolerance and clonal anergy of T cells. Whether Cbl-b can trigger the immune response to weak antigens such as those present in malaria vaccines, or to tumor antigens, is currently the focus of our investigation.

Figure 1: Proposed Cbl-b regulated signaling pathways in T cells. (See e.g. Bachmaier et al. Nature; Krawczyk et al. Immunity; Jeon et al. Immunity).
Taken together, our data established the molecular hierarchy by which components of NF-κB activation pathway become recruited to the immune synapse, identified the molecular mechanism by which the adapter protein Carma1 couples antigen receptor signaling to IKK and NF-κB activation in T cells, and provided the first genetic evidence of a new class of molecular scaffold essential for the selective recruitment of defined signaling machinery, i.e. IKK, into specific regions of immune synapses. To further dissect the signaling hierarchies of TCR-mediated immune synapse formation essential for effective T cell activation we have begun to analyze a novel Carma1 binding partner that also binds to other CARD-containing proteins and a cytoskeletal protein that associates with PKCθ.

**Carma1 in T cell activation**

T cell activation depends on the contact between T cell receptors (TCRs) and agonistic peptides displayed by major histocompatibility complex (MHC) expressed on antigen presenting cells (APCs). TCR-mediated stimulation results in the assembly of antigen receptors, signaling molecules and lipid rafts into superamolecular activation clusters (SMACs) at the interface between T cells and APCs. Based on the structural similarity to neural synapses, SMACs are also referred to as immune synapses. Deficiencies of proteins such as the exchange factor Vav1 that affect immune synapse formation result in impaired T cell activation (Figure 1).

MAGUK (membrane–associated guanylate kinase)-family proteins have been shown to control the polarity of membrane domains at epithelial cell junctions and to function in the formation and/or organization of the immune synapses in lymphocytes. Carma1/CARD11/Bimp3 is a caspase recruitment domain (CARD)-containing MAGUK family protein that is abundantly expressed in lymphoid tissues. Using gene targeting, we have recently demonstrated that Carma1 plays an essential role in antigen receptor-induced NF-κB and JNK activation, and that loss of Carma1 abrogates T cell proliferation and cytokine production. We showed that Carma1 acts downstream of immune synapse formation and PKC activation, controls entry of IKK into lipid raft aggregates and, most importantly, into the central SMAC areas at the immune synapse (Figure 2). Carma1-regulated recruitment of both IKK and Bcl10 into lipid rafts is, however, differently regulated (Figure 3).
Mechanisms underlying cell motility and guidance

The migration of cells is essential to life, as a primary feature of developmental and repair processes. It also contributes to disease states, such as in the dissemination of malignant cells during metastasis. We address questions of how the process of cell motility is driven and controlled.

Guiding the way with microtubules

One area of our research programme addresses the question of how a cell polarises to move in a given direction. We now know that cell motility relies on the dynamic formation and reorganisation of actin filaments that form the „actin cytoskeleton“. But in many cells, polarisation requires the „microtubule cytoskeleton“ and our investigations are aimed at revealing how microtubules exert their influence on the turnover of the actin cytoskeleton to confer this polarisation.

The dependence on microtubules for polarisation generally parallels the degree of anchorage of a cell with the substrate, namely with the extent of formation of „focal adhesions“. Our recent work has provided evidence for the involvement of microtubules in focal adhesion turnover. Thus, we have shown that the growing ends of microtubules specifically target focal adhesions and that multiple targeting events lead to focal adhesion disassembly, or their release from the substrate. Focal adhesion formation requires the development of tension in the actin cytoskeleton, and results with tension inhibitors provide support for the idea that microtubules destabilise adhesions by delivering a factor(s) that promotes relaxation locally at the targeted adhesion sites. More recently, we applied the technique of total internal reflection fluorescence (TIRF) to living cells and have shown that microtubules approach focal adhesions in a range of nanometres, consistent with an exchange of molecular signals between the two.

The idea that interactions of microtubules with the „cell cortex“ are involved in morphogenetic processes has been substantiated in studies of diverse biological systems, from yeast to eukaryotes. A striking development in the field is the realization that microtubules accumulate at their growing tips a complex of protein components that appears
to influence microtubule dynamics and mediate cortical interactions. In budding yeast, for example, the proper orientation of the mitotic spindle requires the guidance of microtubules along actin cables into the bud tip through cooperation of the microtubule tip protein Bim1 and a myosin V (Myo2) mediated by the adaptor protein Kar9. Our future studies are directed at defining the means of guidance of microtubules into adhesion sites in vertebrate cells and the nature of the signalling events, focusing attention on the molecular complexes that accumulate at microtubule tips and in focal adhesions. These studies will exploit the TIRF method for analysing microtubule-cortical interactions.

Pushing forward

The first stage of cell movement involves the protrusion of a thin layer of cytoplasm, termed the lamellipodium, which is driven by the polymerisation of actin. The lamellipodium, together with integrated bundles, called filopodia, serve, in turn, to initiate adhesion with the substrate. Understanding the structural basis of motility requires a knowledge of the organisation of the actin networks that make up the protrusive lamellipodia of migrating cells. Divided opinions about the mode of generation and assembly of actin filament networks in lamellipodia have however arisen through discrepancies in results obtained by different preparative techniques used for electron microscopy. To help resolve current controversies we have initiated the application of cryo-electron microscopy for investigations of cytoskeleton architecture. In parallel studies we are developing techniques for the correlation of the motile activity of the living cell in the light microscope, with the ultrastructure in the EM. Future aims include the characterization of actin reorganizations leading to adhesion formation and defining the relative functional roles of lamellipodia and filopodia.

Additional information may be obtained from our website:
http://cellix.imba.oeaw.ac.at/Videotour/video_tour_1.html

Figure 2: Microtubule tips target focal adhesions in the nanometre range. Total Internal Reflection Fluorescence Microscopy (TIRF) of a cell transfected with Ds-Red zyxin (focal adhesions) and eGFP CLIP-170 (a microtubule tip component). (C) shows accumulated video frames of regions boxed in (B). In this imaging mode, a fluorescence signal is obtained only from structures situated within around 150nm of the substrate. The images show that microtubule tips target focal adhesions within this range.

Figure 3: Cryo-EM image of the actin network in the lamellipodium of a fibroblast cytoskeleton.
The sequencing of the complete genomes of humans and several model organisms has revealed the entire set of genes that direct all the complex biological processes underlying their development and physiology. The major challenge now is to assign functions to each of these genes – this is the goal of functional genomics. The success of functional genomics relies on a set of reagents and procedures for systematically perturbing the function of each and every gene in an organism’s genome. Significant new insights into complex multicellular processes will require that such gene perturbation studies be performed in the intact, living organism. A further requirement, necessitated by the pleiotropy of gene function, is that gene perturbation be restricted as far as possible to the tissues or cells of interest.

Genome-wide, tissue-specific gene perturbation studies are currently feasible in only a single multicellular organism: Drosophila melanogaster. RNAi can be triggered in Drosophila by the spatially and temporally controlled expression of an RNAi transgene, which produces a potent and tissue-specific RNAi effect (Figure 1). In the Drosophila RNAi group, we are constructing a library of transgenic RNAi strains, comprising over 20,000 lines – 1 or 2 lines for each of the 13,681 genes in the Drosophila genome. This library should be completed during 2005. From preliminary tests, we estimate that over 70% of the lines are effective. And by testing RNAi lines for genes for which classical loss-of-function mutations are available, we know that the effect is both potent and specific (Figure 2).

In Drosophila, RNAi can be triggered in vivo from transgenes that produce “hairpin” RNAs. With this approach, it is possible to perturb the function of almost any gene in any cell or tissue at any time. We are constructing a genome-wide library of such transgenes, to enable systematic surveys of gene function in vivo.

We will exploit this library in academic research at IMBA, and strive to make it available to the academic research community worldwide. For commercial exploitation, the library will be licenced to the newly-founded Ludwig Boltzmann Institute of Functional Genomics, which will be housed within the IMBA building and commence operation during 2005.

Contact: barry.dickson@imba.oeaw.ac.at
georg.dietzl@imba.oeaw.ac.at

Figure 1: Transgenic RNAi in Drosophila. The generic GAL4/UAS system is used to drive the expression of a hairpin RNA (hpRNA). These double-stranded RNAs are processed by Dicer into siRNAs, which direct sequence-specific degradation of the target mRNA.

Figure 2: RNAi phenotypes. (A) Control with GAL4 driver only. (B) GAL4 driver + UAS-eyRNAi, targeting the eyeless gene. The eye is missing, as in the eyeless mutant. (C) Wing hairs in a wild type fly all point in the same direction. (D) GAL4 driver + UAS-fmiRNAi, targeting flamingo, a gene required for planar cell polarity. The wing hairs are misorientated, as in the flamingo mutant.

Contact: barry.dickson@imba.oeaw.ac.at
georg.dietzl@imba.oeaw.ac.at

Drosophila RNAi group

Barry Dickson / Senior Scientist
Georg Dietzl / PhD Student

Yulia Barinova / Technical Assistant
Silvia Bicker / Technical Assistant
Michaela Fellner / Technical Assistant
Martha Garstkiewicz / Technical Assistant
Beate Gasser / Technical Assistant
Karin Jäger / Technical Assistant
Kuan-Chung Su / Technical Assistant
Silvia Oppel / Technical Assistant

1 FWF; 2 part-time; 3 EU Project FLYSNP

Barry Dickson / Senior Scientist
Georg Dietzl / PhD Student

Yulia Barinova / Technical Assistant
Silvia Bicker / Technical Assistant
Michaela Fellner / Technical Assistant
Martha Garstkiewicz / Technical Assistant
Beate Gasser / Technical Assistant
Karin Jäger / Technical Assistant
Kuan-Chung Su / Technical Assistant
Silvia Oppel / Technical Assistant

1 FWF; 2 part-time; 3 EU Project FLYSNP
Biooptics Department

The services offered by our department to the researchers at the IMP and IMBA cover flow cytometry and cell sorting, a wide variety of microscopic techniques, image analysis and processing as well as cDNA-microarray production and analysis.

Flow cytometry

This year, in response to increasing demands for multicolor flow cytometric analyses, a new FACScanto flow cytometer was installed allowing acquisition of data from cells simultaneously labelled with up to six different fluorochromes.

Microscopy and image analysis

The major accomplishment of the microscopy unit in 2004 was the establishments of a variety of 4D-technologies that utilize laser scanning and spinning disk confocal microscopy, wide-field fluorescence microscopy and deconvolution technology. As the number of users and the amount of generated images steadily increases, an institute-wide database system for image management is currently being implemented.

Microarrays

This year we were able to dramatically improve the quality of our cDNA-microarrays by reengineering almost all of the steps of the array production. The generation and purification of the PCR-products is now highly automated, and, by changing the buffer conditions the printing of arrays is independent of environmental conditions such as temperature and humidity. The improved quality of the arrays allows faster and more reliable analysis of the data. An additional benefit of the reengineering is an approx. 50% reduction of the costs per array.

Together with the group of Thomas Jenuwein at the IMP, we are building up the infrastructure and technology to generate a high-resolution epigenetic map of the mouse chromosome 17 using the ChIP-on-chip technology. So far we have produced microarrays enabling us to map the non-repetitive sequences with an average resolution of approximately 15kb. Next year we plan to increase the resolution to 5kb. To refine our methodology we are yet optimizing array production, sample preparation and downstream analysis. In addition, in order to visualize the data, a web-based epigenome-browser is being developed in collaboration with Insilico Software, Vienna. The browser will be inter-connected with other tools and databases available in our department.

Contact: steinlein@imp.univie.ac.at

Peter Steinlein / Staff Scientist
Sebastian Carotta1 / Postdoc
Volker Leidl / Software Architect
Karin Paiha / Microscopy and Imaging
Pawel Pasierbek2 / Microscopy and Imaging
Martin Radolf / Microarrays
Gabriele Stengl / Flow Cytometry

1until August 2004
2since September 2004

Figure: Example of a ChIP-on-chip experiment. First generation genomic array is hybridized with input DNA (red) and anti-Trimethyl-H3-K4 (green) from mouse embryo fibroblasts. (Data provided by Joost Martens, Group Jenuwein, IMP).
Service Department

The Service Department offers a variety of high quality and rapid services to the IMP and IMBA scientists. The majority of our efforts involve DNA sequencing and preparation of various media and solutions.

Sequencing and DNA isolation

Using two ABI 3100 Genetic Analyzer capillary sequencers, and, since June, an additional ABI 3730 DNA Analyzer, we sequenced approximately 41,000 samples in the first 9 months of this year (see figure). This is a substantial increase as compared with 2003. The increase has been caused not only by the acquisition of “new customers” from IMBA but also by generally higher number of requests and “genetic screens” as compared with the previous years. The average read-length on both capillary sequencers, the 3100 Genetic Analyzers equipped with the 80 cm capillaries, and the 3730 DNA Analyzer equipped with the 50 cm capillaries, is comparable (700-900 bases) for standard DNA samples. However, the 3730 DNA Analyzer is more sensitive and requires smaller amounts of expensive reagents, and of DNA. For both platforms we employ the same easy and fast clean-up protocol with Sephadex columns on a 96-well microtiter plate.

Production of antibodies

Our department is also responsible for the production and isolation of continuously increasing amounts and varieties of monoclonal antibodies in hybridomas, and for organizing the antibody production in rabbits with an outside company.

Preparation of solutions and media

Our Media Kitchen prepares substantial quantities of reagent quality solutions and media for cell culture, D. melanogaster (approximately 500,000 bottles and tubes per year) and C. elegans. We also prepare many selected reagents such as DNA molecular weight markers, enzymes, a variety of transformation-competent E.coli strains, and maintain a stock of cloning vectors, primers and other cloning reagents.

Contact: schaffner@imp.univie.ac.at

Figure: A sequencing run on an ABI 377 PRISM and number of reactions analyzed on ABI 377 (1997 - 2001), on ABI 3100 (2001 - 2004) and on ABI 3730 (since June 2004) done with dye deoxy terminators (v3.1) in the years 1997 to 2004 (scale 0 to 60,000).

* Calculated from January 2004 to September 2004 data

Gotthold Schaffner / Scientist
Ivan Botto / Technician
Markus Hohl / Technician
Shahryar Taghybeeglu / Technician
Gabriele Botto / Technician Media Kitchen
Franziska Stranksy / Technician Fly Food Preparation
Ulrike Windholz / Technician Media Kitchen
Oliver Botto / Part-time Help Fly Food Preparation
Anna Windholz / Part-time Help Fly Food Preparation
Shotgun 2D Proteomics

Tandem mass spectrometry (MS/MS) experiments generate short stretches of sequence information but in most cases only a small fraction of all generated peptides can be recovered and analyzed. To overcome this problem we developed a “shotgun” approach: Protein complexes are purified by immunoprecipitation and digested by different enzymes, the generated peptides are separated by multi-dimensional liquid chromatography and analyzed by MS/MS. By combining the high sensitivity and the resolution of nanoscale multi-dimensional liquid chromatography with the precise structural specificity of MS/MS spectral data the sites and types of modifications are identified in large portions of the sequence of the protein complexes. This approach is particularly important for analyzing the structure of multi-subunit protein complexes. In addition we designed a web-based program called “Mascot Protein Extractor” (see figure) for rapid merging and comparing of sequence search engine results from multiple LC-MS/MS peptide analysis (http://extractor.imp.univie.ac.at).

Figure: Mascot Extractor-software for merging and comparing mass spectrometry data.

Post-translational modifications

Protein phosphorylation is the most important reversible post-translational modification. Thus, analysis of phosphorylated proteins and identification of the phosphorylation sites helps us to understand their biological functions. Our group develops strategies to improve the sensitivity and selectivity of phosphorylation analysis techniques such as:
- Immobilized metal affinity chromatography (IMAC)
- Beta-Elimination of the phosphate group and Michael addition with 2-aminoethanethiol
- Neutral loss and precursor ion scan with our new QTRAP 4000 mass spectrometer.

Post-translational modifications of histones, e.g. methylation, can modulate transcription according to the ‘histone code’ hypothesis. Mass spectrometry (MS) has proven a valuable tool to identify and quantify changes in histone methylation patterns. In quantitative MS, it is essential to correct for different efficiencies of ionization and detection of differentially modified peptides. These efficiencies are measured using isotopically labeled synthetic peptides as external standards. The labeled peptides are excellent tools for proteomics and are used in applications ranging from absolute quantification of protein abundance and modifications to determination of complex stoichiometry.

Peptides and antibodies

We synthesize about 150 peptides per year, including an increasing number of branched peptides containing acetylated, phosphorylated or methylated amino acid residues and isotopically labeled peptides for protein quantification. The affinity purification of antibodies is performed under mild conditions.

Contact: mechtler@imp.univie.ac.at
Animal House

Husbandry

The husbandry is divided into three main areas containing the following species: mice, chicken and *Xenopus*. The largest area is the mouse section, where more than 10,000 mice are kept. These comprise breeding colonies, stock, and experimental animals including many transgenic and knock-out mouse lines. To provide a constant supply of mice for the various projects, 20 standard strains are routinely bred in-house.

Animal house services

*Veterinary services*, such as monitoring of the facility’s health-status (sentinel-program etc.), experimental procedures in animals such as collection of blood, implantation of tumor cells and administration of substances by iv, ip or sc injections. All procedures are performed to a high standard under appropriate anaesthetic regimes and in conjunction with the necessary project licenses.

*Animal procurement*, such as ordering of mice from external breeding companies, organizing and handling of approximately 50 incoming and outgoing mouse-shipments per year.

*Administration of regulatory affairs* in accordance with the Austrian laboratory animal law, which include record-keeping and updating of laboratory animal statistics, and specific documentation of laboratory animal experiments.

Mouse Service

The Mouse Service Department was set up at the beginning of 1998 to cope with the increasing demand for mouse studies and generation of transgenics. The Mouse Service Department services are shared by the IMP and IMBA.

The main duties of this service unit are the injection of ES cells into blastocysts (also tetraploid) and of DNA into the pronucleus of fertilized mouse eggs. This service also provides for the transfer of ‘clean’ embryos into our animal house, the freezing of embryos for the preservation of specified mouse strains and the teaching of basic embryological techniques to the IMP and IMBA staff. *In vitro* fertilization experiments (IVF) are performed and the mouse strain database is kept up-to-date. About 30 different ES cell clones and several DNA constructs are being successfully injected per year. The activities of this department are overseen by an Animal User Committee, which meets bimonthly to set priorities and to coordinate the duties. At present, it is chaired by Erwin F. Wagner.

Contact: theussl@imp.univie.ac.at

Animal House & Mouse Service Department

Contact: bichl@imp.univie.ac.at

Animal House

Andreas Bichl / Head, Veterinarian
Erwin F. Wagner / Scientific Coordinator
Norma Howells / Consultant
Mijo Dezic / Technician
Katja Flahndorfer-Stepanek / Technician
Sabine Häckl / Technician
Sabine Jungwirth / Technician
Erika Kiligan / Technician
Milan Lazic / Technician
Elisabeth Pölzlauer / Technician
Esther Rauscher / Technician
Alexandra Stepanek / Technician

Mouse Service Department

Hans-Christian Theussl / Technician
Awards and honours

Joerg Betschinger
Received the award from the Austrian Society for Biochemistry and Molecular Biology for his PhD thesis (September 2004).

Barry Dickson
Elected EMBO Member (October 2004).

Karl Mechtler
Received a science prize of the federal state of Lower Austria for his research in protein chemistry (September 2004).

Josef Penninger
Elected Austrian Scientist of the Year 2003 (January 2004).
Honorary Professor, University of Vienna (February 2004).
Kennedy Visiting Professor, London (March 2004).
Elected to the Deutsche Akademie der Naturforscher Leopoldina as Full Member (October 2004).
Austria04’ Award (October 2004).
The Koy Lecture, Trinity College, Toronto (October 2004).
The Harold Copp Lecture, Vancouver (October 2004).
Honorary Professor, Peking Union Medical College (December 2004).
Member of the New York Academy of Sciences (December 2004).
The administrative and other service groups provide our researchers with the necessary support in the respective areas and consist of IMP and IMBA members which jointly offer their services to both institutes.

**GENERAL ADMINISTRATION**

Engelbert BERGER           Head of Controlling (IMP)
Birgit GRUBER              Secretary (part-time; IMP)
Larissa KAHR               Grants Manager (IMP)
Werner LEITNER            Head of Personnel Department (IMP)
Sabine SVOBODA             Personnel Officer (part-time; IMP)
Brigitte WEISER           Chief Accountant (IMP)
Anita SOMMER               Assistant Accountant (IMBA)
Eva-Maria RUDLOF          Secretary (part-time; IMP)
Renate BICHLER            Travel Agent (IMP; until March)
Robert LAEZTZY           General Assistant / Driver (IMP)

**PUBLIC RELATIONS**

Heidemarie HURTL          Public Relations Officer (part-time; IMP)

**PURCHASE DEPARTMENT**

Friedrich KUNTNER             Head of Purchase Department (IMP)
Kashinath MITRA            Store Manager (IMP)
Angela GANGLBERGER          Secretary (IMP)
Brigitte LENZ              Secretary (IMBA)
Nikolaus KUNTNER          Warehouseman (part-time; IMBA)
**LIBRARY**

- Susanne VRBA
- Wolfgang GÖSCHL

Chief Librarian (part-time; IMP)
Assistant Librarian (part-time; IMP)

**WASHING KITCHEN**

- Nuray KILIC
- Erika KLEIN
- Renate STIX
- Renate WÖHRER

Laboratory Technician (IMP)

**CAFETERIA**

- Michael ENZBERGER
- Markus GIGLER
- Helga MEHOFER
- Sabine SMALCL
- Güler CICOS
- Selma YILDIRIM

Chef de Cuisine (IMP)
Junior Chef (IMP)
Buffet (IMP)
Buffet (part-time; IMP)
Washing up (part-time; IMP)
Washing up (part-time, IMBA)

**BIOINFORMATICS SERVICE**

*(provided by the IMP group of Frank Eisenhaber)*

**IT SERVICE DEPARTMENT**

- Andreas RIEPL
- Werner KUBINA
- Herlind WURTH

IT System Manager (IMP)
IT System Manager (IMP)
IT System Manager (IMBA)

**GRAPHICS DEPARTMENT**

- Hannes TKADLETZ
- Jola GLOTZER

Graphics Service (IMP)
Web Maestra (part-time; IMP)

**TECHNICAL DEPARTMENT**

- Alexander CHLUP
- Martin COLOMBINI
- Nadir AYKUT
- Christian DAVID
- Vladimir KOLCAR
- David KUMMERER
- Gerhard MÜLLER
- Martin ROJDL
- Grete KOCHNA

Chief Engineer (IMP)
Mechanical Workshop (IMP)
House Maintenance (IMP)
House Maintenance (IMP)
House Maintenance (IMP)
Technical Maintenance (IMBA)
Technical Maintenance (IMP)
House Maintenance (IMBA)
Receptionist (part-time; IMP)
**Publications (since IMBA’s incorporation)**

**GROUP DICKSON**

(2003)


(2004)


**GROUP KNOBLICH**

(2004)


**GROUP MARTINEZ**

(2004)

**GROUP PENNINGER**

(2002)


expression of ANG-(1-7) and ACE2 during pregnancy. Hypertension 42, 749-53.


Krawczyk, C., Oliveira-dos-Santos, A., Sasaki, T., Griffiths, E., Ohashi, P. S., Snap-

Kurrer, M. O., Kopf, M., Penninger, J., and Eriksson, U. (2002). Cytokines that regu-

Mate, M. J., Ortiz-Lombardia, M., Boitel, B., Haouz, A., Tello, D., Susin, S. A., Pen-

Matsumoto, G., Tsumenatsu, S., Tsukinoki, K., Ohmi, Y., Iwamiya, M., Oliveira-dos-

and Katada, T. (2002). SEK1/MKK4-Mediated SAPK/JNK Signaling Participates in

Roumier, T., Vieira, H. L., Castedo, M., Ferri, K. F., Boya, P., Andreau, K., Druillennec,


Giuriato, S., Pesesse, X., Bodin, S., Sasaki, T., Viala, C., Marion, E., Penninger, J.,

Gonzalez-Espinosa, C., Odom, S., Olivera, A., Hobson, J. P., Martinez, M. E., Oliveri-

Suzuki, N., Suzuki, S., Duncan, G. G., Millar, D. G., Wada, T., Mirtsos, C., Takada, H.,

Wakeham, A., Itie, A., Li, S., Penninger, J. M., Wesche, H., Ohashi, P. S., Mak, T. W.,

and Yeh, W. C. (2002). Severe impairment of interleukin-1 and Toll-like receptor

Griffiths, E. K., Sanchez, O., Mill, P., Krawczyk, C., Hojilla, C. V., Rubin, E., Nau M. M.,

Kim, C., Marchal, C. C., Penninger, J., and Dinauer, M. C. (2003). The Hemopoi-

Griffiths, E. K., Dinauer, M. C., Kucharska, E. M., Hara, H., Penninger, J. M., Domashenz, H.,

Griffiths, E. K., Sanchez, O., Mill, P., Krawczyk, C., Hojilla, C. V., Rubin, E., Nau, M. M.,


3-kinases in immunity: lessons from knockout mice. J. Biochem. (Tokyo) 131,

495-501.

Tani-Ishii, N., Penninger, J. M., Matsumoto, G., Teranaka, T., and Umemoto, T.

(2002). The role of LFA-1 in osteoclast development induced by co-cultures of

mouse bone marrow cells and MC3T3-G2/PA6 cells. J. Periodontal Res. 37,

184-91.


Watanabe, T., Nakagawa, K., Ohata, S., Kitagawa, D., Nishitani, G., Seo, J., Tane-

mura, S., Shimizu, N., Kishimoto, H., Wada, T., Aoki, I., Arai, H., Iwatsubo, T., Mo-

chita, M., Satake, M., Ito, Y., Matsuyama, T., Mak, T., Penninger, J., Nishina, H.,

and Katada, T. (2002). SEK1/MKK4-Mediated SAPK/JNK Signaling Participates in

Embryonic Hepatoblast Proliferation via a Pathway Different from NF-kappaB-

Induced Anti-Apoptosis. Dev. Biol. 50, 332-47.


expression of ANG-(1-7) and ACE2 during pregnancy. Hypertension 42, 749-53.

Cheng, H. Y., and Penninger, J. M. (2003). When the DREAM is gone: from basic

science to future prospects in pain management and beyond. Expert Opin.

Ther. Targets 7, 249-63.

Crackower, M. A., Kolas, N. K., Noguchi, J., Sarao, R., Kikuchi, K., Kaneko, H., Ko-
bayashi, E., Kawai, Y., Koziarzadki, I., Landers, R., Mo, R., Hui, C. C., Nieves, E.,

Cohen, P. E., Osborne, L. R., Wada, T., Kunieda, T., Moens, P. B., and Penninger, J.

M. (2003). Essential role of Fkbp6 in male fertility and homologous chromosome

pairing in meiosis. Science 300, 1291-5.

two Aces. J. Mol. Biol. 31, 227-34.

Eriksson, U., Kurrer, M. O., Sonderegger, I., Jeaz, G., Tafuri, A., Hunziker, L., Suzuki,


Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the


Eriksson, U., Ricci, R., Hunziker, L., Kurrer, M. O., Oudit, G. Y., Watts, T. H., Son-

induced autoimmune heart failure requires cooperation between adaptive and


Giuriato, S., Pesesse, X., Bodin, S., Sasaki, T., Viala, C., Marion, E., Penninger, J.,

Schurmans, S., Erneus, C., and Payrastro, B. (2003). SH2 domain containing ino-
sitol 5-phosphatasases 1 and 2 in blood platelets: interaction and respective role

in the control of phosphatidylinositol 3,4,5-trisphosphate level. Biochem. J. 376,

199-207.

Gonzalez-Espinosa, C., Odom, S., Olivera, A., Hobson, J. P., Martinez, M. E., Oliveri-


Preferential Signaling and Induction of Allergy-promoting Lymphokines Upon


197, 1453-65.

Griffiths, E. K., Sanchez, O., Mill, P., Krawczyk, C., Hojilla, C. V., Rubin, E., Nau M. M.,

Khokha, R., Lipkowitz, S., Hui, C. C., and Penninger, J. M. (2003). Cbl-3-Defi-


Hara, H., Wada, T., Bakal, C., Koziarzadki, I., Suzuki, S., Suzuki, N., Nghiem, M.,

Griffiths, E. K., Krawczyk, C., Bauer, B., D’Acquisto, F., Ghosh, S., Yeh, W. C., Baier,


essential for lymphocyte activation. Immunity 18, 763-75.

Heximer, S. P., Knutsen, R. H., Sun, X., Kaltenbronn, K. M., Rhee, M. H., Peng, N.,

Olivera-Dos-Santos, A., Penninger, J. M., Muslin, A. J., Steinberg, T. H., Wyss, J. M.,

Mecham, R. P., and Blumer, K. J. (2003). Hypertension and prolonged vasoco-


Jun, J. E., Wilson, L. E., Vinuesa, C. G., Lesage, S., Blyer, M., Miosge, L. A., Cook,

M. C., Kucharska, E. M., Ohashi, P. S., Snap-

thionyl-Leucyl-Phenylalanine-Activated Neutrophil Functions. J. Immunol. 171,

2444-53.
Publications


(2004)


GROUP SMALL

(G2003)


## Seminar Speakers

### January

<table>
<thead>
<tr>
<th>Date</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.01.04</td>
<td>Peter Staller (ETH Zürich)</td>
<td></td>
</tr>
<tr>
<td>13.01.04</td>
<td>Masahiko Harata (Grad. School of Agric. Sci., Tohoku Univ., Japan)</td>
<td></td>
</tr>
<tr>
<td>15.01.04</td>
<td>Niklaus Pfanner (Univ. of Freiburg, Germany)</td>
<td></td>
</tr>
<tr>
<td>16.01.04</td>
<td>Ron Hay (Univ. of St. Andrews, Scotland)</td>
<td></td>
</tr>
<tr>
<td>20.01.04</td>
<td>Sebastian Fugmann (Yale School of Med.)</td>
<td></td>
</tr>
<tr>
<td>22.01.04</td>
<td>Gloria Luciani (Univ. of Dundee)</td>
<td></td>
</tr>
<tr>
<td>22.01.04</td>
<td>Jain Mattai (EML, Heidelberg)</td>
<td></td>
</tr>
<tr>
<td>27.01.04</td>
<td>Johanna Joyce (UCSF)</td>
<td></td>
</tr>
<tr>
<td>28.01.04</td>
<td>Mike van den Bosch (Univ. of Galway, Ireland)</td>
<td></td>
</tr>
<tr>
<td>29.01.04</td>
<td>Diego Lorayza (Rockefeller Univ.)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### February

<table>
<thead>
<tr>
<th>Date</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>05.02.04</td>
<td>Luk Van Paris (Center for Cancer Res., Cambridge, MA)</td>
<td></td>
</tr>
<tr>
<td>05.02.04</td>
<td>Maria Pia Postiglione (Stazione Zoologica, Naples, Italy)</td>
<td></td>
</tr>
<tr>
<td>17.02.04</td>
<td>Daniel Tenen (Harvard Inst. of Med., Boston)</td>
<td></td>
</tr>
<tr>
<td>19.02.04</td>
<td>Gerald H. Pollack (Univ. of Washington, Seattle)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### March

<table>
<thead>
<tr>
<th>Date</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>04.03.04</td>
<td>Nick Brown (Univ. of Cambridge)</td>
<td></td>
</tr>
<tr>
<td>11.03.04</td>
<td>Susan Gasser (Univ. of Geneva)</td>
<td></td>
</tr>
<tr>
<td>12.03.04</td>
<td>Jomuna V. Choudhuri (Bielefeld Univ., Germany)</td>
<td></td>
</tr>
<tr>
<td>16.03.04</td>
<td>Andreas Kungl (Univ. of Graz)</td>
<td></td>
</tr>
<tr>
<td>17.03.04</td>
<td>Stephanie Benesch</td>
<td></td>
</tr>
<tr>
<td>18.03.04</td>
<td>Peter Parker (Lincoln's Inn Fields Lab., London)</td>
<td></td>
</tr>
<tr>
<td>19.03.04</td>
<td>Koichi Matsuo (Keio Univ., Tokyo)</td>
<td></td>
</tr>
<tr>
<td>22.03.04</td>
<td>Tatsugoshi Taniguchi (Univ. of Tokyo)</td>
<td></td>
</tr>
<tr>
<td>23.03.04</td>
<td>Jonathan Weissmann (UCSF)</td>
<td></td>
</tr>
<tr>
<td>24.03.04</td>
<td>Roy Driessen (Univ. of Rotterdam)</td>
<td></td>
</tr>
<tr>
<td>25.03.04</td>
<td>Harald von Boehmer (Harvard Univ.)</td>
<td></td>
</tr>
<tr>
<td>26.03.04</td>
<td>Constanze Bonifer (Univ. of Leeds)</td>
<td></td>
</tr>
<tr>
<td>30.03.04</td>
<td>Katrien Neirynck (Ghent Univ.)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### April

<table>
<thead>
<tr>
<th>Date</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>06.04.04</td>
<td>Joan Massague (Memorial Sloan-Kettering Cancer Center, NY)</td>
<td></td>
</tr>
<tr>
<td>13.04.04</td>
<td>Michael Kiebler (MPI Tuebingen)</td>
<td></td>
</tr>
<tr>
<td>15.04.04</td>
<td>Phil Beachy (The Johns Hopkins Univ., Baltimore)</td>
<td></td>
</tr>
<tr>
<td>16.04.04</td>
<td>Albert Sickmann (Rudolf-Virchow-Center for Exper. Biomed., Wurzburg)</td>
<td></td>
</tr>
<tr>
<td>19.04.04</td>
<td>Ulrich Cortes (IARC, France)</td>
<td></td>
</tr>
<tr>
<td>20.04.04</td>
<td>Rebecca Heald (Univ. of California, Berkeley)</td>
<td></td>
</tr>
<tr>
<td>22.04.04</td>
<td>Mark van Breugel (MPI Dresden)</td>
<td></td>
</tr>
<tr>
<td>23.04.04</td>
<td>Andre Moeller (MPI Goettingen)</td>
<td></td>
</tr>
<tr>
<td>27.04.04</td>
<td>Christopher Baum (MHH Hanover)</td>
<td></td>
</tr>
<tr>
<td>30.04.04</td>
<td>Peter Lenart (EML Heidelberg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### May

<table>
<thead>
<tr>
<th>Date</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>03.05.04</td>
<td>Mariano Barbacid (CNIO, Madrid)</td>
<td></td>
</tr>
<tr>
<td>06.05.04</td>
<td>Juan Carlos Zúñiga-Pflücker (Sunnybrook &amp; Women's College Health Sciences Centre, Toronto)</td>
<td></td>
</tr>
<tr>
<td>06.05.04</td>
<td>Thomas Kiehhaber (Univ. of Basel)</td>
<td></td>
</tr>
<tr>
<td>11.05.04</td>
<td>Frank Lyko (DZK, Heidelberg)</td>
<td></td>
</tr>
<tr>
<td>12.05.04</td>
<td>Tom Luedde (Medical Univ., Hannover)</td>
<td></td>
</tr>
<tr>
<td>13.05.04</td>
<td>Colin Stewart (NCI-FCRDC, Maryland)</td>
<td></td>
</tr>
<tr>
<td>18.05.04</td>
<td>Carol Prives (Columbia Univ., New York)</td>
<td></td>
</tr>
<tr>
<td>19.05.04</td>
<td>Jim Manley (Columbia Univ., New York)</td>
<td></td>
</tr>
<tr>
<td>25.05.04</td>
<td>Joseph Schlessinger (Yale Univ.)</td>
<td></td>
</tr>
<tr>
<td>27.05.04</td>
<td>David Virshup (Univ. of Utah)</td>
<td></td>
</tr>
<tr>
<td>28.05.04</td>
<td>John Condeelis (Albert Einstein College of Med., New York)</td>
<td></td>
</tr>
<tr>
<td>28.05.04</td>
<td>Dirk Schuebeler (FMI, Basel)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### June

<table>
<thead>
<tr>
<th>Date</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>03.06.04</td>
<td>Frank McKeon (Harvard Med. School)</td>
<td></td>
</tr>
<tr>
<td>14.06.04</td>
<td>Gordon Keller (Mount Sinai School of Med., New York)</td>
<td></td>
</tr>
<tr>
<td>18.06.04</td>
<td>Eli Gilboa (Duke Univ. Med. Centre, North Carolina)</td>
<td>(Special Lecture in Memory of Laura Stingl)</td>
</tr>
<tr>
<td>22.06.04</td>
<td>Tom Roberts (Harvard Med. School)</td>
<td></td>
</tr>
<tr>
<td>24.06.04</td>
<td>Gerd Jürgens (Univ. of Tuebingen)</td>
<td></td>
</tr>
<tr>
<td>29.06.04</td>
<td>I. King Jordan (NCBI, Bethesda)</td>
<td></td>
</tr>
<tr>
<td>30.06.04</td>
<td>Andrea Musacchio (Europ. Inst. of Oncology, Milan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### July

<table>
<thead>
<tr>
<th>Date</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>01.07.04</td>
<td>Cornelis J.M. Melief (Leiden Univ. Med. Center, The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>05.07.04</td>
<td>Dave Gilbert (SUNY Upstate Med. Univ., Syracuse, N.Y)</td>
<td></td>
</tr>
<tr>
<td>06.07.04</td>
<td>Henry Roehl (Sheffield Univ.)</td>
<td></td>
</tr>
<tr>
<td>07.07.04</td>
<td>Dominique Ferrandon (IBMC du CNRS, Strasbourg, France)</td>
<td></td>
</tr>
<tr>
<td>15.07.04</td>
<td>Jim Smith (Univ. of Cambridge, UK)</td>
<td></td>
</tr>
<tr>
<td>16.07.04</td>
<td>Gerry Rubin (HHMI)</td>
<td></td>
</tr>
<tr>
<td>26.07.04</td>
<td>Douglas Hanahan (UCSF)</td>
<td></td>
</tr>
<tr>
<td>29.07.04</td>
<td>Ralf Erdmann (Inst. of Physiol. Chem., Bochum, Germany)</td>
<td></td>
</tr>
<tr>
<td>30.07.04</td>
<td>Anton Meinhart (Gene Center, Univ. of Munich)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### August

<table>
<thead>
<tr>
<th>Date</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.08.04</td>
<td>Arndt von Haeseler (Univ. of Duesseldorf)</td>
<td></td>
</tr>
<tr>
<td>19.08.04</td>
<td>Stefan Schuster (Friedrich Schiller Univ., Jena, Germany)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Seminar speakers**
<table>
<thead>
<tr>
<th>Date</th>
<th>Speaker</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.09.04</td>
<td>YOSEF SHILOH (Tel Aviv Univ., Israel)</td>
<td></td>
</tr>
<tr>
<td>03.09.04</td>
<td>DANIEL GELRICH (EMBL Heidelberg)</td>
<td></td>
</tr>
<tr>
<td>06.09.04</td>
<td>SHIGEKATSU KATO (Univ. of Tokyo)</td>
<td></td>
</tr>
<tr>
<td>09.09.04</td>
<td>DAVID SIDEROSKI (UNC-Chapel Hill School of Med.)</td>
<td></td>
</tr>
<tr>
<td>09.09.04</td>
<td>JERRY WORKMAN (Stowers Inst. for Med. Res., Kansas City)</td>
<td></td>
</tr>
<tr>
<td>10.09.04</td>
<td>CHRIS DOE (Inst. of Neurosci./HHMI, Oregon)</td>
<td></td>
</tr>
<tr>
<td>15.09.04</td>
<td>JIMENA WEIBEZAHN (ZMBH, Heidelberg)</td>
<td></td>
</tr>
<tr>
<td>16.09.04</td>
<td>ALFRED WITTINGHOFER (MPI Dortmund)</td>
<td></td>
</tr>
<tr>
<td>17.09.04</td>
<td>JASON D. FONTENOT (Univ. of Washington, Seattle)</td>
<td></td>
</tr>
<tr>
<td>23.09.04</td>
<td>CHARLOTE BOONE (Banting and Best Dept. of Med. Res., Toronto)</td>
<td></td>
</tr>
<tr>
<td>01.10.04</td>
<td>YOSHINORI YAMASHITA (Dept. of Oncology, Pharm. Res. Centre of Kyowa Hakko Kogyo Co. Ltd.)</td>
<td></td>
</tr>
<tr>
<td>12.10.04</td>
<td>JUERG BAEHLER (The Wellcome Trust Sanger Inst., Cambridge)</td>
<td></td>
</tr>
<tr>
<td>18.10.04</td>
<td>HALLGUIR RUI (Georgetown Univ., Washington DC)</td>
<td></td>
</tr>
<tr>
<td>19.10.04</td>
<td>MARC REHMSMEIER (Univ. of Bielefeld)</td>
<td></td>
</tr>
<tr>
<td>20.10.04</td>
<td>GRAHAM ANDERSON (Dept. of Anatomy, Inst. for Biomed. Res., Univ. of Birmingham)</td>
<td></td>
</tr>
<tr>
<td>20.10.04</td>
<td>LAURE STROCHLIC (Univ. of Cambridge)</td>
<td></td>
</tr>
<tr>
<td>22.10.04</td>
<td>PHILIPP SELENKO (Harvard Med. School, Boston)</td>
<td></td>
</tr>
<tr>
<td>22.10.04</td>
<td>VINCENT ARCHAMBAULT (Rockefeller Univ.)</td>
<td></td>
</tr>
<tr>
<td>28.10.04</td>
<td>HANS SCHOELER (MPI Muenster)</td>
<td></td>
</tr>
<tr>
<td>29.10.04</td>
<td>WOLFGANG FISCHLE (Lab. of Chromatin Biol., The Rockefeller Univ., New York)</td>
<td></td>
</tr>
<tr>
<td>03.11.04</td>
<td>JIRI FRIML (ZMBP, Univ. of Tuebingen)</td>
<td></td>
</tr>
<tr>
<td>04.11.04</td>
<td>STEFAN UHLIG (Leibniz Center for Med. and Bioscience)</td>
<td></td>
</tr>
<tr>
<td>08.11.04</td>
<td>DONALD F. HUNT (Depts. of Chem. and Path., Univ. of Virginia, Charlottesville, Virginia)</td>
<td></td>
</tr>
<tr>
<td>12.11.04</td>
<td>JEROEN DOBBELAERE (Inst. of Biochem., Zurich)</td>
<td></td>
</tr>
<tr>
<td>12.11.04</td>
<td>INKA PAWILITZKY (Univ. of Massachusetts, Boston)</td>
<td></td>
</tr>
<tr>
<td>16.11.04</td>
<td>TOM A. RAPOPORT (Harvard Med. School, Dept. of Cell Biol.)</td>
<td></td>
</tr>
<tr>
<td>18.11.04</td>
<td>JOHN SCOTT (Howard Hughes Med. Inst., Portland, USA)</td>
<td></td>
</tr>
<tr>
<td>23.11.04</td>
<td>TON ROLINK (Univ. of Basel)</td>
<td></td>
</tr>
<tr>
<td>25.11.04</td>
<td>ALEXANDER JOHNSON (UCSF)</td>
<td></td>
</tr>
<tr>
<td>26.11.04</td>
<td>PATRICK MATTHIAS (FMI, Basel)</td>
<td></td>
</tr>
</tbody>
</table>
Scientific Advisory Board

In order to maintain the highest standard of research IMBA, together with the IMP, has installed a process of review and feedback: the Scientific Advisory Board (SAB), consisting of internationally recognised scientists. The Board meets yearly at IMBA, and, together with IMBA researchers, discusses the quality, the significance, and the main focus of research conducted at IMBA.

Members of the Scientific Advisory Board

Prof. Frederick W. Alt  
Harvard Medical School, Boston, USA

Dr. Dr. Andreas Barner  
Boehringer Ingelheim GmbH, Ingelheim, Germany

Prof. Tyler Jacks  
MIT Department of Biology, Cambridge, USA

Prof. Rudolf Jaenisch  
The Whitehead Institute, Cambridge, USA

Prof. Herbert Jäckle  
MPI für biophysikalische Chemie, Göttingen, Germany

Prof. Sir David Lane  
University of Dundee, Dundee, UK

Prof. Titia de Lange  
Rockefeller University, New York, USA

Prof. Steve McKnight  
Southwestern Medical Center, Dallas, USA

Prof. Gregory A. Petsko  
Brandeis University, USA

Dr. Wolfgang Rettig  
Boehringer Ingelheim, Austria, Vienna
Supervisory Board

The Supervisory Board of IMBA serves as advisor to and monitors the actions of the management team on a regular basis. It consists of six persons with a strong background in academic science and medicine, legal and tax affairs, auditing and other areas of business administration.

Members of the Supervisory Board

Prof. Dr. Peter Schuster / Chairman
Institute for Theoretical Chemistry and Structural Biology, University of Vienna, Austria

Prof. Dr. Josef Aicher / Deputy Chairman
Institut für Handels- und Wirtschaftrecht, University of Vienna, Austria

Prof. Dr. Dkfm. Oskar Grün
Institute of Supply Management, Vienna University of Economics and Business Administration, Austria

Prof. Dr. Josef Smolen
Department of Rheumatology, Internal Medicine III, University of Vienna, Austria

Prof. Dr. Michael Lang
Department of Austrian and International Tax Law, Vienna University of Economics and Business Administration, Austria

Mag. Gottfried Schellmann
Chairman of Technologie Impulse Gesellschaft and Partner of KPMG Niederösterreich GmbH, Austria
Social life